AQ4N in Combination With Radiotherapy and Temozolomide in Subjects With Newly Diagnosed Glioblastoma Multiforme
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Phase 1b of the study, will evaluate the safety and tolerability of AQ4N treatment at three
different dose levels.
Phase 2a of the study, will further evaluate the safety, tolerability, and in addition
efficacy of AQ4N treatment at a tolerated dose selected from Phase 1b.